Special Issue "Antituberculosis Drugs"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 August 2012)

Special Issue Editor

Guest Editor
Dr. Marcelo J. Nieto
Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026-2000, USA
E-Mail: mnieto@siue.edu
Interests: drug design; parallel synthesis; antibacterials; antimalarials; antimycobacterials; natural products; antivirals

Special Issue Information

Dear Colleagues,

Tuberculosis (TB), a disease cause by Mycobacterium tuberculosis (Mt), is one of the deadliest infectious diseases. Each year almost 2 million people die worldwide according to estimates from the World Health Organization (WHO). The treatment for tuberculosis is more than 30 years old and includes a multidrug approach during a long period of time (6-9 months). There are several resistant strains of Mt including multidrug (MDR) strains resistant to more than one first line drugs and extremely resistant strains (XDR), resistant to first and second line drugs. These strains have made Mt and TB very difficult to treat and eradicate. This special issue will focus on the biology of Mt, resistance, new targets, drug discovery and development, and clinical trials.

Dr. Marcelo J. Nieto
Guest Editor

Keywords

  • Mycobacterium tuberculosis
  • TB resistance
  • drug discovery
  • mode of action
  • clinical trials
  • drug development
  • opportunistic infections

Published Papers (5 papers)

Pharmaceuticals 2012, 5(11), 1210-1235; doi:10.3390/ph5111210
Received: 27 August 2012; in revised form: 25 October 2012 / Accepted: 2 November 2012 / Published: 9 November 2012
Show/Hide Abstract | Download PDF Full-text (517 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2012, 5(11), 1147-1159; doi:10.3390/ph5111147
Received: 29 August 2012; in revised form: 8 October 2012 / Accepted: 16 October 2012 / Published: 25 October 2012
Show/Hide Abstract | Download PDF Full-text (506 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Pharmaceuticals 2012, 5(9), 1021-1031; doi:10.3390/ph5091021
Received: 13 August 2012; in revised form: 10 September 2012 / Accepted: 11 September 2012 / Published: 17 September 2012
Show/Hide Abstract | Download PDF Full-text (200 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2012, 5(8), 882-889; doi:10.3390/ph5080882
Received: 2 July 2012; in revised form: 24 July 2012 / Accepted: 3 August 2012 / Published: 23 August 2012
Show/Hide Abstract | Download PDF Full-text (179 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2012, 5(7), 690-718; doi:10.3390/ph5070690
Received: 15 May 2012; in revised form: 12 June 2012 / Accepted: 21 June 2012 / Published: 28 June 2012
Show/Hide Abstract | Download PDF Full-text (227 KB) | Download XML Full-text

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert